retatrutide trials FDA Approval Status 2026: Everything We Know So Far Today, we shared new data

Several factors contribute: Insurance networks - Joining insurance networks requires contracting, credentialing, and claims submission infrastructure Coverage limitations - Many insurance plans do not cover GLP-1 medications for weight loss (vs

Wang JY et al

Potential benefit - A patient whose biomarkers suggest rapid metabolism of GLP-1 drugs might be offered a longer-acting formulation, while someone with strong GIP responsiveness could start on a dual-agonist right away, avoiding months of trial-and-error

Arch Gynecol Obstet (2015) 292(4):74956

This page covers projected timelines based on clinical trial progress

Two things matter about these numbers